CANADA —Asep Medical Holdings has entered into a debt agreement with a third-party private lender to obtain a US$ 1 million non-revolving term credit facility. The financing carries an annual interest rate of 12% and matures over a 24-month timeline, with terms allowing for full or partial early repayment without penalty. To secure the funding, the company pledged its existing and future personal assets as collateral, covering account balances, equipment, inventory, intellectual property, and contractual rights. Disbursements can be requested in single or multiple tranches within five days of notification, subject to standard closing prerequisites and regulatory approval from the Canadian Securities Exchange.
Based in Victoria, Canada, Asep Medical Holdings is a biotechnology investment enterprise specializing in the commercialization of intellectual property for medical diagnostics and therapies. The entity holds interest in specialized firms developing sepsis diagnostic systems and anti-biofilm medical treatments based on research originating from the University of British Columbia.
The injection of debt capital provides necessary liquidity to manage daily operational expenditures and short-term cash flow needs without triggering immediate equity dilution for existing shareholders, as no common shares, warrants, or finder's fees were tied to the transaction. However, encumbering core corporate assets—including key intellectual property—under a general security arrangement underscores the heightened strategic priority placed on maintaining short-term financial stability.
For the broader biotechnology sector, where early-stage clinical research and commercialization cycles often require extended financial runway, secured debt instruments represent a critical bridge mechanism when equity capital markets are tight or costly. The reliance on asset-backed debt reflects ongoing liquidity challenges faced by micro-cap life science firms balancing long-term research development with immediate working capital obligations.
Investors and market participants will monitor the company's ability to generate cash flows or secure long-term equity financing prior to the 24-month debt maturity, ensuring asset protection while maintaining commercial momentum across its medical technology subsidiaries.
